An experimental gene therapy being developed by a Chinese company has restored hearing in children with congenital deafness, researchers working on a clinical trial reports, adding to growing evidence of the efficacy of such treatments.
Subscribe now for unlimited access.
or signup to continue reading
Five of six young children with profound deafness experienced hearing recovery and improvements in speech recognition six months after treatment with the therapy from Refreshgene Therapeutics, according to the report published in The Lancet.
"The results from this study are truly remarkable. We saw the hearing ability of children improve dramatically week by week, as well as the regaining of their speech," Zheng-Yi Chen of Mass Eye and Ear and Harvard Medical School, who worked on the trial, said in a statement.
All of the children had profound deafness caused by mutations of the OTOF (otoferlin) gene.
A functioning otoferlin protein is necessary for the transmission of the sound signals from the ear to the brain.
OTOF mutations account for two per cent to eight per cent of cases of congenital deafness, earlier research suggests.
One out of every 1000 children born in the US has moderate to profound hearing loss.
In surgical procedures performed at the Eye & ENT Hospital of Fudan University, researchers used a harmless virus to carry a version of the human OTOF gene into patients' inner ears.
After 26 weeks, five of the six children demonstrated hearing recovery, with dramatic improvements in speech perception and the ability to conduct conversation, the researchers reported.
Most side effects were minor and none had long-term impact, they said.
The researchers are not sure why the sixth child did not respond.
One possible explanation is that some of the gene therapy solution leaked from the inner ear during or after surgery.
Refreshgene is also working with OBiO Technology Shanghai on a gene therapy for the eye disease neovascular age-related macular degeneration.
On Tuesday, a separate team of researchers announced hearing restoration in an 11-year-old who was the first patient to receive Eli Lilly's OTOF gene therapy.
In October, Regeneron Pharmaceuticals announced positive safety and efficacy results in the first child with profound OTOF-related hearing loss to receive its otoferlin gene therapy.
Updated results from these trials will be presented at the Association for Research in Otolaryngology MidWinter Meeting in February.
Australian Associated Press
